Prognostic value of clinical, laboratory, and histological characteristics in multiple myeloma: Improved definition of risk groups
- 1 January 1993
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 29 (7) , 978-983
- https://doi.org/10.1016/s0959-8049(05)80205-9
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Prognostic importance of labelling index in myelomatosisScandinavian Journal of Haematology, 2009
- Prognostic factors in multiple myeloma:* The M.D. Anderson experienceEuropean Journal of Haematology, 2009
- A plea to overcome the concept of “staging” and related inadequacy in multiple myelomaEuropean Journal of Haematology, 1991
- Long‐term prognostic value of serum β2microglobulin in myelomatosisBritish Journal of Haematology, 1990
- A new prognostic system for multiple myeloma based on easily available parametersBritish Journal of Haematology, 1989
- Induction and maintenance therapy in multiple myeloma: a multicenter trial of MP versus VCMPEuropean Journal of Cancer and Clinical Oncology, 1988
- Prognostic value of serum lactic dehydrogenase (S‐LDH) in multiple myelomaEuropean Journal of Clinical Investigation, 1987
- The Serum Levels and Urinary Excretion of β2-Microglobulin in Apparently Healthy SubjectsScandinavian Journal of Clinical and Laboratory Investigation, 1972
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958